A 58-year-old man with acute leukemia undergoing induction chemotherapy develops persistent fever (38.5°C) and a new pulmonary infiltrate on chest X-ray despite 5 days of broad-spectrum antibiotics (piperacillin-tazobactam + amikacin). Blood and respiratory cultures remain negative. Serum galactomannan antigen is positive. What is the most appropriate immediate next step?

Explanation

## Clinical Diagnosis: Invasive Aspergillosis This patient has hallmark features of invasive aspergillosis (IA) in a high-risk immunocompromised host: - Severe neutropenia (from chemotherapy) - Persistent fever despite antibiotics - Pulmonary infiltrate - **Positive serum galactomannan antigen** — a highly specific biomarker for invasive Aspergillus infection ## Diagnostic Significance of Galactomannan **Key Point:** Serum galactomannan antigen positivity in a neutropenic patient with fever and pulmonary infiltrate is diagnostic of invasive aspergillosis until proven otherwise. It warrants immediate antifungal therapy without waiting for culture confirmation. **High-Yield:** Galactomannan is a cell wall polysaccharide of Aspergillus species. Its detection in serum has >90% specificity and 60–80% sensitivity for invasive IA. A positive result in this clinical context is sufficient to initiate therapy. **Clinical Pearl:** Waiting for culture results (which take 5–7 days) or performing additional imaging delays critical treatment. Invasive aspergillosis in neutropenic patients has high mortality if antifungal therapy is delayed. ## First-Line Antifungal Agents for Invasive Aspergillosis | Agent | Mechanism | Indication | Advantage | Disadvantage | |-------|-----------|-----------|-----------|---------------| | Voriconazole | Azole (CYP450 inhibitor) | First-line for IA | Excellent lung penetration, oral bioavailability | Drug interactions, visual disturbances | | Liposomal amphotericin B | Polyene | First-line alternative | Broad spectrum, rapid fungicidal action | Nephrotoxicity, infusion reactions | | Posaconazole | Azole | Salvage therapy | Good activity, fewer interactions | Lower bioavailability | | Echinocandins | β-glucan synthase inhibitor | Adjunctive only | Minimal interactions | Poor CNS penetration, not monotherapy | **Mnemonic:** **VAMP** = **V**oriconazole or **A**mphotericin B (liposomal) are **M**ost **P**owerful for invasive aspergillosis. ## Management Algorithm ```mermaid flowchart TD A[Neutropenic fever + pulmonary infiltrate]:::outcome --> B{Galactomannan antigen?}:::decision B -->|Positive| C[Invasive aspergillosis diagnosed]:::outcome B -->|Negative| D[Continue clinical monitoring]:::action C --> E{Renal function adequate?}:::decision E -->|Yes| F[Start voriconazole IV]:::action E -->|No/Concern| G[Start liposomal amphotericin B]:::action F --> H[Monitor clinical response<br/>repeat imaging day 7]:::action G --> H H --> I[Defervescence + infiltrate improvement]:::outcome ``` **Key Point:** Voriconazole is preferred if renal function is normal; liposomal amphotericin B is preferred in renal impairment or if voriconazole is contraindicated.